These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16237088)

  • 1. Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies.
    Mulder A; Eijsink C; Kester MG; Franke ME; Kardol MJ; Heemskerk MH; van Kooten C; Verreck FA; Drijfhout JW; Koning F; Doxiadis II; Claas FH
    J Immunol; 2005 Nov; 175(9):5950-7. PubMed ID: 16237088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
    Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
    Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.
    Fangmann J; Dalchau R; Fabre JW
    J Exp Med; 1992 Jun; 175(6):1521-9. PubMed ID: 1588278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of HLA-DR1/DRB1*0101 molecules presenting HLA-A2 derived peptides by a human recombinant antibody, Fab-5 A1.
    Löffler D; Welschof M; Goldmann SF; Wölpl A
    Eur J Immunogenet; 1998 Oct; 25(5):339-47. PubMed ID: 9805656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
    Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
    J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
    Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
    Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies.
    Ravindranath MH; Taniguchi M; Chen CW; Ozawa M; Kaneku H; El-Awar N; Cai J; Terasaki PI
    Mol Immunol; 2010 Feb; 47(5):1121-31. PubMed ID: 19944464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.
    Martayan A; Sibilio L; Tremante E; Lo Monaco E; Mulder A; Fruci D; Cova A; Rivoltini L; Giacomini P
    J Immunol; 2009 Mar; 182(6):3609-17. PubMed ID: 19265139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies.
    Burlingham WJ; Jankowska-Gan E; DeVito-Haynes L; Fechner JH; Hogan KT; Claas FH; Mulder A; Wang X; Ferrone S
    J Immunol; 1998 Dec; 161(12):6705-14. PubMed ID: 9862700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
    Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
    Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells.
    Kobayashi H; Kimura S; Aoki N; Sato K; Celis E; Katagiri M
    Immunogenetics; 2001 Oct; 53(8):626-33. PubMed ID: 11797095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
    Lev A; Novak H; Segal D; Reiter Y
    J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.
    Qian J; Wang Q; Xiao L; Xiong W; Xian M; Su P; Yang M; Zhang C; Li Y; Zhong L; Ganguly S; Zu Y; Yi Q
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38267222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies.
    Held G; Luescher IF; Neumann F; Papaioannou C; Schirrmann T; Sester M; Smola S; Pfreundschuh M
    J Immunol; 2015 Nov; 195(9):4210-7. PubMed ID: 26416277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of the monoclonal antibody W6/32: sensitivity to the amino terminus of beta2-microglobulin.
    Shields MJ; Ribaudo RK
    Tissue Antigens; 1998 May; 51(5):567-70. PubMed ID: 9672158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
    Inaguma Y; Akahori Y; Murayama Y; Shiraishi K; Tsuzuki-Iba S; Endoh A; Tsujikawa J; Demachi-Okamura A; Hiramatsu K; Saji H; Yamamoto Y; Yamamoto N; Nishimura Y; Takahashi T; Kuzushima K; Emi N; Akatsuka Y
    Gene Ther; 2014 Jun; 21(6):575-84. PubMed ID: 24694533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides.
    Lo Monaco E; Sibilio L; Melucci E; Tremante E; Suchànek M; Horejsi V; Martayan A; Giacomini P
    J Immunol; 2008 Oct; 181(8):5442-50. PubMed ID: 18832701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.